Summary
Clinical pharmacologic studies have been carried out in patients with head and neck tumors following 36-h continuous infusions of high-dose MTX (1.5 g/m2). The results indicated considerable variation in the amount of MTX in the blood of individual patients. To control these variations, a modified protocol was set up to try to attain the same MTX blood level in all subjects. The protocol has a pharmacokinetic basis and involves determination of the MTX kinetics in each patient. The information thus obtained allows us to compute a 36-h infusion dose so that the MTX plasma levels never exceed a threshold beyond which there is a risk of toxicity to the host.
The computation is validated by taking a blood sample 6 h after the beginning of the infusion. If the MTX concentration is higher than its expected value, the infusion rate can then be immediately reduced. Analytical methods that will allow such a computation, the results of the clinical application of this pharmacokinetic approach, and some implications of such a method are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bertino, J. R.: “Rescue” techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Semin. Oncol. 4, 203 (1977)
Bertino, J. R., Fischer, G. A.: Techniques for study of resistance to folic acid antagonists. Methods Med. Res. 10, 297 (1964)
Bishoff, K. B., Dedrick, R. L., Zaharko, D. S., Longstreth, J. A.: Methotrexate pharmacokinetics. J. Pharm. Sci. 60, 1128 (1971)
Bleyer, W. A.: Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat. Rev. 4, 87 (1977)
bleyer, W. A.: The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 41, 36 (1978)
Cano, J. P., Rigault, J. P., Aubert, C., Carcassonne, Y., Seitz, J. P.: Determination of 5-fluorouracil in plasma by GC/MS using an internal standard: applications to pharmacokinetics. Bulletin du Cancer 1, 67 (1979)
Chabner, B. A.: Threshold methotrexate concentration for “in vivo” inhibition of DNA synthesis in normal and tumorous target tissues. Clin. Invest. 52, 1804 (1973)
Chabner, B. A., Slavik, M.: Introduction: perspectives on high-dose methotrexate (NSC-740) therapy. Cancer Chem. Rep. Part 3, 6, (1975)
Chabner, B. A., Myers, C. E. Olivero, V. T.: Clinical pharmacology of anticancer drugs. Semin. Oncol. 4, 165 (1976)
Chabner, B. A., Stoller, R. G., Hande, K., Jacobs, S., Young, R. C.: Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. Drug. Metab. Rev. 8, 107 (1978)
Creaven, P. J., Mihich, E.: The clinical toxicity of anticancer drugs and its predictions. Semin. Oncol. 4, 147 (1977)
Creaven, P. J., Cohen, M. H., Allen L. M.: Methotrexate plasma decay kinetics: possible alterations in patients undergoing gut sterilization. Br. J. Cancer 34, 571 (1976)
Dedrick, R. L., Zaharko, D. S., Lutz, R. J.: Transport and binding of methotrexate “in vivo”. J. Pharm. Sci. 62, 882 (1973)
Leme, P. R., Creaven, P. J., Allen, L. M., Berman, M.: Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chem. Rep. Part 1, 59, 811 (1975)
Monjanel, S.: Contribution à l'étude pharmacocinétique de deux anticancéreux: Méthotrexate et 5-Fluorouracile—Thèse d'Etat en Pharmacie, Marseille (in preparation, 1979)
Myers, C. E., Lippman, M. E., Eliot, H. M., Chabner, B. A.: Competitive protein binding assay for methotrexate. Med. Sci. 72, 3683 (1975)
Stoller, R. G., Jacobs, S. A., Drake, J. C., Lutz, R. J., Chabner, B. A.: Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chem. Rep. 6, 19 (1975)
Author information
Authors and Affiliations
Additional information
with the technical collaboration of F. Baratier
Rights and permissions
About this article
Cite this article
Monjanel, S., Rigault, J.P., Cano, J.P. et al. High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach. Cancer Chemother. Pharmacol. 3, 189–196 (1979). https://doi.org/10.1007/BF00262421
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262421